Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases.

Autoimmun Rev

Division of Rheumatology, Department of Medicine, University of Padova, Via Giustiniani 2 35128 Padova, Italy.

Published: July 2011

Annexins are a group of 12 highly conserved proteins which exert several regulatory functions on cell biology. There are involved in numerous cell processes including vesicle trafficking, calcium signaling, cell growth, division, and apoptosis. Autoantibodies directed toward annexin I, II, V and XI have been reported, but their role and their clinical correlates are controversial. Annexin I exerts an anti-inflammatory effect by suppressing the generation of inflammatory mediators and anti-annexin I antibodies were detected in patients affected with rheumatoid arthritis, systemic (SLE) and cutaneous lupus erythematosus. Annexin II and V have a high affinity for phospholipids playing a pivotal role in the regulation of coagulation cascade. Anti-annexin II and anti-annexin V antibodies were found in patients with arterial or venous thrombosis, especially in those with autoimmune rheumatic diseases (ARD) such as SLE, primary antiphospholipid syndrome (APS) or systemic sclerosis. Anti-annexin V antibodies were also found in patients with pregnancy loss with or without APS. Annexin XI is involved in several biological pathways, particularly apoptosis and cell proliferation. Anti-annexin XI antibodies have been found in patients with SLE, undifferentiated connective tissue disease, rheumatoid arthritis, Sjögren's syndrome and APS. The metanalysis of studies published up to now showed that the Odds Ratio for having an ARD in anti-annexin XI positive patients was 5.08 (95% CI 2.06-12.58).

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2011.04.007DOI Listing

Publication Analysis

Top Keywords

anti-annexin antibodies
16
antibodies patients
12
rheumatoid arthritis
8
syndrome aps
8
anti-annexin
6
patients
5
anti-annexins autoantibodies
4
autoantibodies role
4
role biomarkers
4
biomarkers autoimmune
4

Similar Publications

Prevalence of antiphospholipid antibodies in COVID-19 patients: A meta-analysis.

Vascul Pharmacol

December 2024

Department of Geriatric, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, Zhejiang Province, China; Zhejiang Provincial Key laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Major Chronic Disease in the Elderly, Hangzhou 310006, Zhejiang Province, China. Electronic address:

Objective: In some reports, antiphospholipid antibodies (aPL) prevalence is higher in COVID-19 patients. This study intended to compare aPL prevalence between COVID-19 patients and healthy controls, and differences in aPL types using meta-analysis.

Methods: This work retrieved published literature about association between COVID-19 and aPL from Embase, Web of Science, PubMed, and The Cochrane Library databases.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the presence of anti-podocyte antibodies, specifically targeting synaptopodin and annexin 1, in patients with nephrotic syndrome to evaluate their role in diagnosing primary podocytopathies like Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS).
  • A total of 72 nephrotic syndrome patients were analyzed, alongside 21 healthy individuals, finding higher antibody levels in MCD and FSGS patients compared to the others, indicating their potential use in diagnosis.
  • The combined analysis of both antibody types showed significant diagnostic accuracy (sensitivity of 80.9% and specificity of 81.3%), although these antibody levels did not predict how well patients
View Article and Find Full Text PDF

Laboratory measurement of autoantibodies to Annexin A1: Review and measurements in health and COVID-19.

Transfus Apher Sci

December 2024

Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, the Netherlands; Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands.

Annexin A1, a protein released by neutrophils, is a potent regulator of inflammation in the intact form, but loses this activity when cleaved. The presence of autoantibodies to this protein can impact its function. An immunoassay, developed to measure autoantibodies to Annexin A1 in plasma or serum, has been developed and performances are reported.

View Article and Find Full Text PDF

Objective: This study aims to evaluate the correlation between anti-annexin A5 (aANXA5) antibody in the blood and pregnancy outcomes .

Methods: This study is a retrospective cohort study based on singleton pregnancies of the Third Affiliated Hospital of Wenzhou Medical University from May 2018 to December 2022. Baseline characteristics were collected from all participants.

View Article and Find Full Text PDF

Criteria and non-criteria antiphospholipid autoantibodies screening in patients with late pregnancy morbidity: A cross-sectional study.

Placenta

September 2024

Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France; Université Paris Cité, Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS ERL8252, Faculté de Médecine site Bichat, Laboratoire d'Excellence Inflamex, Paris, France. Electronic address:

Introduction: Antiphospholipid syndrome (APS) is a cause of pregnancy morbidity. We aim to determine the frequency of criteria and non-criteria anti-phospholipid (aPL) autoantibodies in patients admitted for unexplained fetal death (UFD), pre-eclampsia (PE) and/or fetal growth restriction (FGR).

Methods: All consecutive patients with UFD, PE and/or FGR followed in the department of Obstetrics, Bichat Hospital, University of Paris, Paris, between January 2019 and December 2021 were screened.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!